L-Ofloxacin
Acute Leukemia Of Ambiguous Lineage
Children's Oncology GroupSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
43 Active assets in the Acute Leukemia Of Ambiguous Lineage cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide SWOG Cancer Research Network | Phase 2 | BB |
Cytarabine SWOG Cancer Research Network | Phase 2 | B |
METHOTREXATE SWOG Cancer Research Network | Phase 2 | B |
Vincristine sulfate Children's Oncology Group | Phase 2 | B |
Fludarabine Janssen Research & Development, LLC | Phase 2 | B |
View all 50 →
Same molecule, other indications
L-Ofloxacin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →